Evidence map›Paper›PMID 34888749›Full record

ReviewCurrent hypertension reports2021

Lipoprotein (a) and Hypertension.

Natalie C Ward, Janis M Nolde, Justine Chan, Revathy Carnagarin, Gerald F Watts, Markus P Schlaich

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Journal of the American Heart Association · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?International journal of molecular sciences · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Natalie C WardDobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.
Janis M NoldeDobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.
Justine ChanDobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.
Revathy CarnagarinDobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.
Gerald F WattsMedical School, University of Western Australia, Perth, Australia.
Markus P SchlaichDobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia. markus.schlaich@uwa.edu.au.ORCID 0000-0002-1765-0195
The University of Western Australia · AUBaker Heart and Diabetes Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo provide an overview of the associations between elevated blood pressure and lipoprotein (a) and possible causal links, as well as data on the prevalence of elevated lipoprotein (a) in a cohort of hypertensive patients. RECENT

findingsElevated lipoprotein (a) is now considered to be an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Despite this, there are limited data demonstrating an association between elevated lipoprotein (a) and hypertension. Further, there is limited mechanistic data linking lipoprotein (a) and hypertension through either renal impairment or direct effects on the vasculature. Despite the links between lipoprotein (a) and atherosclerosis, there are limited data demonstrating an association with hypertension. Evidence from our clinic suggests that ~ 30% of the patients in this at-risk, hypertensive cohort had elevated lipoprotein (a) levels and that measurement of lipoprotein (a) maybe useful in risk stratification.

Indexed as

Aortic Valve StenosisCalcinosisHypertensionAortic ValveHumansLipoprotein(a)Risk FactorsLipoprotein(a)AtherosclerosisCardiovascular riskDyslipidemiaHypertensionLipoprotein (a)Renal functionVascular function

Identifiers

PMID34888749
OpenAlexW4200495534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.